LumiraDx Limited (LMDX)
| Previous close | 0.0160 |
| Open | 0.0211 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.0151 - 0.0282 |
| 52-week range | 0.0151 - 0.0282 |
| Volume | |
| Avg. volume | N/A |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Roche (RHHBY) to Acquire LumiraDx's Point of Care Technology
Roche (RHHBY) is set to acquire LumiraDx's Point of Care technology for $295 million and an additional payment of up to $55 million.
- Reuters
Roche to buy part of LumiraDx diagnostics platform for $295 million
Swiss drugmaker Roche said on Friday it has agreed to buy LumiraDx's Point of Care diagnostics platform business for about $295 million. Shares of LumiraDx rose about 20%, to 76 cents in aftermarket trading. The transaction is expected to close by mid-2024, after which the acquired segment will become a part of Roche's diagnostics unit, the drugmaker said.
- Zacks
LumiraDx Limited (LMDX) Loses -25.54% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
LumiraDx Limited (LMDX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
